Research Article

Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients

Table 5

Details and outcome of HCV-positive patients.

Patient Child* R-IPIπ HPS#Baseline
before RCHOP
During
RCHOP
Hepatic toxicity Last follow-up
after RCHOP
Viral reactivation (≥1  over the baseline) Response Outcome/OS
(months)
ALT (U/L) HCV-RNA (IU/mL) ALT peak Cycle GradeEnzyme flare ALT HCV-RNA
(ALT > 3ULN)Onset from initiation of R-CHOP (days)HCV-RNA during flare

1A5GI302,360,000407th0No255,420,000NoCRAlive/19
2A5GL26814,800603rd1No20630,250NoCRAlive/17
3A6GL3034,500484th1No263,671,000YesCRAlive/20
4A5GI75320,400805th 1No60970,821NoCRAlive/19
5A5GI992,172,6501125th1No404,972,532NoCRAlive/18
6A5GL71127,8351322nd 2Yes28575,40720639,015NoPRAlive/18
7A6PH5492,6281244th 2Yes94235,0002879,236YesPRDied/7.8

Child classification (A5-6 = well-compensated disease). πR-IPI score (G = good, P = poor outcome). #HPS = HCV prognostic score differentiating between three risk categories (L = low, I = intermediate, and H = high). The ALT ULN = 40 IU/L.